KR20190050690A - Lipolytic composition containing phosphocholine derivatives - Google Patents

Abstract

The present invention relates to a lipolytic composition containing a specific phosphocholine derivative or a pharmaceutically acceptable salt thereof, for example, a pharmaceutical composition for preventing or treating obesity comprising local obesity. The pharmaceutical composition of the present invention not only has an excellent lipolytic activity, but also exhibits a uniform lipolytic activity. In addition, the pharmaceutical composition of the present invention can minimize adverse effects such as inflammation, tissue necrosis and the like at an administration site. Further, the pharmaceutical composition of the present invention has excellent storage stability.

Description

[0001] The present invention relates to a lipolytic composition containing phosphocholine derivatives,

The present invention relates to a fat-degrading composition comprising a phosphocholine derivative or a pharmaceutically acceptable salt thereof, for example a pharmaceutical composition for the prophylaxis or treatment of obesity.

Fat is the excess energy consumed as food, accumulated in white adipose tissue, and the condition is usually referred to as obesity because of the accumulation of excessive white adipose tissue. It is called lipolysis that the breakdown of triglyceride into free fatty acid (FFA) and glycerol by the action of hormone sensitive lipase (HSL).

Liposuction, which is a surgical operation, is being performed to improve obesity. Liposuction, also known as lipoplasty or liposculpture suction lipectomy, is a cosmetic surgery that removes fat from various parts of the body. It is used for a variety of abdominal, thigh, hip, neck, Lt; / RTI > However, liposuction can cause serious side effects, including wounding, swelling, paralysis and burning of the surgical site, risk of infection, damage to the skin or nerves, or perforation of critical organs. In addition, there is also a risk associated with anesthesia because it requires significant treatment and recovery periods and requires local anesthesia or, in some cases, general anesthesia in the surgical procedure.

Phosphocholine (Phosphocholine, PC) is a phospholipid introduced with choline as a head group and widely known to animals, plants, yeast, and fungi, and is also called lecithin or unsaturated lecithin. It is mainly contained in cerebral waters, nerves, blood cells, egg yolk and the like in mammals, and is contained in soybean, sunflower seed, wheat germ, and the like in plants. Since phosphatidylcholine has four double bonds in the molecule, it is easily oxidized during the preparation or during storage and the structure is deformed. To overcome these disadvantages, the form of saturated lecithin prepared by adding hydrogen to unsaturated lecithin has been developed. U.S. Patent Publication No. US2005 / 0287199 discloses a method of reducing adipose tissue comprising injecting lecithin. In addition, U.S. Patent Publication No. US2016 / 0339042 discloses a method for reducing local adipose tissue comprising topically administering a composition comprising lecithin and a bile acid or salt thereof to proximal or distal adipose tissue. However, when lipid degradation is induced by locally injecting lecithin, side effects such as erythema, inflammation, tissue necrosis, edema, dimpling and the like are generated. Further, when the lecithin-containing preparation is stored for a long period of time, Further, there is a problem that the lipolytic activity is lowered.

The present inventors have conducted various studies to develop a fat-degrading composition having excellent fat-degrading activity and formulation stability and showing no side effects, for example, a pharmaceutical composition for preventing or treating obesity. The present inventors evaluated the activity, side effects, and stability of various choline derivatives, and found that a preparation containing a specific phosphocholine derivative had superior to conventional phosphatidylcholine-containing preparations and had uniform lipolytic activity and stability However, it has been found that side effects such as inflammation, tissue necrosis and the like at the site of administration can be minimized.

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating obesity containing a specific phosphocholine derivative as an active ingredient.

The present invention also provides a method of inducing fat degradation or a method of treating obesity comprising administering a therapeutically effective amount of said phosphocholine derivative to a mammal in need of induction of fat decomposition or treatment of obesity .

It is another object of the present invention to provide a use of the above-mentioned phosphocholine derivative for use in the production of a medicament for inducing lipolysis or preventing or treating obesity.

According to one aspect of the present invention there is provided a pharmaceutical composition for the prevention or treatment of obesity comprising as an active ingredient a therapeutically effective amount of a compound of formula 1: < EMI ID = 2.1 >

≪ Formula 1 >

Wherein,

X and Y are, independently of one another, C ₉ ~C ₁₇ alkyl group; Or a C ₁₅ -C ₂₁ alkenyl group having one or two double bonds,

X and Y can not simultaneously be a C ₁₇ alkyl group; And X and Y can not be a C ₁₇ alkenyl group having two double bonds at the same time.

In the pharmaceutical composition of the present invention, the compound of Formula 1 may be 1,2-dideckanoyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1,2-diylcoyl-sn-glycero-3-phosphocholine; 1,2-diolureo-sn-glycero-3-phosphocholine; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; And 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. More preferably, the compound of Formula 1 is 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; And 1,2-dilauroyl-sn-glycero-3-phosphocholine. Most preferably, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine.

The pharmaceutical composition of the present invention may further comprise a therapeutically effective amount of bile acid or a pharmaceutically acceptable salt thereof. Wherein the bile acid is selected from the group consisting of cholic acid, glycolic acid, glyco deoxycholic acid, deoxycholic acid, taurocholic acid, ursodeoxycholic acid, taurosoldoxycholic acid, taurodeoxycholic acid, cenodeoxy At least one member selected from the group consisting of glycolic acid, glycolic acid, glycolic acid, glycolic acid, glycolic acid, glycolic acid, glycolic acid, glycolic acid, At least one member selected from the group consisting of sorbic acid, ursodeoxycholic acid, glycoordoxoxycholic acid, sodium deoxycholate, and sodium taurocholate. In one embodiment, the weight ratio of the compound of Formula 1, or a pharmaceutically acceptable salt thereof, to the bile acid or a pharmaceutically acceptable salt thereof may range from 0.5 to 40: 1.

The pharmaceutical composition of the present invention may be formulated into a preparation for parenteral administration, and the parenteral administration preparation may be a transdermal preparation, a subcutaneous preparation, a preparation for intravenous administration, a preparation for intramuscular administration, It can be the first. In addition, the parenteral preparation may be in the form of a liquid preparation or a dry powder preparation, preferably in the form of a solution, emulsion or lyophilized powder. Wherein the parenteral dosage form comprises at least one pharmaceutically acceptable additive selected from the group consisting of a pH adjusting agent, an isotonic agent, a surfactant, a stabilizer, a preservative, a chelating agent, a buffer, and a lyophilized stabilizer; And a pharmaceutically acceptable carrier selected from the group consisting of an oil, an organic solvent, and an aqueous solvent.

According to another aspect of the present invention there is provided a method of inducing fat degradation or treating obesity comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof, A method of inducing a harm or a method of treating obesity is provided.

In the treatment method of the present invention, the compound of Formula 1 is 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1,2-diylcoyl-sn-glycero-3-phosphocholine; 1,2-diolureo-sn-glycero-3-phosphocholine; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; And 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. More preferably, the compound of Formula 1 is 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; And 1,2-dilauroyl-sn-glycero-3-phosphocholine. Most preferably, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine.

According to a further aspect of the present invention there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above for use in the manufacture of a medicament for the prevention or treatment of fatigue induction or obesity.

In the use of the present invention, the compound of Formula 1 is 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1,2-diylcoyl-sn-glycero-3-phosphocholine; 1,2-diolureo-sn-glycero-3-phosphocholine; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; And 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. More preferably, the compound of Formula 1 is 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; And 1,2-dilauroyl-sn-glycero-3-phosphocholine. Most preferably, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine.

The pharmaceutical composition of the present invention containing a specific phosphocholine derivative, that is, the compound of the formula (1) or a pharmaceutically acceptable salt thereof, not only has a superior lipolytic activity as compared with conventional phosphatidylcholine-containing preparations but also has a uniform lipolytic activity . In addition, the pharmaceutical composition of the present invention can minimize adverse effects such as inflammation and tissue necrosis at the administration site. In addition, the pharmaceutical composition of the present invention has excellent storage stability. Therefore, the pharmaceutical composition of the present invention can prevent uneven distribution of subcutaneous fat and aesthetic damage caused thereby, and thus can be usefully used for prevention and treatment of obesity, especially local obesity.

Figs. 1A and 1B show the lipolytic activity of non-administration sites (circles indicated by dashed lines) and administration sites (deep circles) in rats to which the preparation of the present invention was administered, rats to which the preparations of the comparative examples were administered, and control rats Observation results are shown.
FIG. 2 shows the result of hematoxylin and eosin staining of subcutaneous fat extracted from the rats to which the preparation of the present invention was administered, the rats to which the preparation of the comparative example was administered, and control rats, And the same side effect is measured.
FIG. 3 is a graph showing the results of measuring the effects of the oil lipid O (Oil Red O) reaction on the subcutaneous fat extracted from the rats to which the preparation of the present invention was administered, the rats to which the preparation of the comparative example was administered and the control rats . In Fig. 3, the smaller the red oil size, the better the fat is decomposed.
Fig. 4 shows the results of evaluating the stability of the preparations of the present invention and the comparative examples after storage at room temperature for 7 days and 30 days. The first, second, and third containers of each panel exhibit properties immediately upon preparation, storage at room temperature for 7 days, and storage at room temperature for 30 days.

The specific phosphocholine derivatives according to the present invention have excellent and uniform lipolytic activity, and minimize side effects such as inflammation and tissue necrosis. Thus, they can be effectively applied to prevention or treatment of obesity, especially local obesity. Accordingly, the present invention provides a pharmaceutical composition for preventing or treating obesity comprising the phosphocholine derivative as an active ingredient. Specifically, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity, which comprises a therapeutically effective amount of a compound of the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:

≪ Formula 1 >

Wherein,

X and Y are, independently of one another, C ₉ ~C ₁₇ alkyl group; Or a C ₁₅ -C ₂₁ alkenyl group having one or two double bonds,

X and Y can not simultaneously be a C ₁₇ alkyl group; And X and Y can not be a C ₁₇ alkenyl group having two double bonds at the same time.

Preferably, in the pharmaceutical composition of the present invention, the compound of Formula 1 may be selected from the group consisting of the following compounds:

1,2-didecanoyl-sn-glycero-3-phosphocholine (DDPC);

Di-lauroyl-sn-glycero-3-phosphocholine (DLPC);

1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC); 1,2-dimyristoyl-sn-glycero-3-phosphocholine;

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);

1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC); 1-myristicoyl-2-palmitoyl-sn-glycero-3-phosphocholine;

1-myristoyl-2-stearoyl-sn-glycero-3? Phosphocholine (MSPC); 1-myristoyl-2-stearoyl-sn-glycero-3?

1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine, PMPC);

1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, PSPC);

1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (SMPC); 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine;

1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC);

1,2-dierucoyl-sn-glycero-3-phosphocholine (DEPC);

1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine;

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC);

1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC).

More preferably, in the pharmaceutical composition of the present invention, the compound of Formula 1 may be selected from the group consisting of the following compounds:

1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC);

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);

1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (SMPC);

1,2-didecanoyl-sn-glycero-3-phosphocholine (DDPC);

1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC); And

Di-lauroyl-sn-glycero-3-phosphocholine (DLPC).

Most preferably, in the pharmaceutical composition of the present invention, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).

The compound of the above formula (1) or its salt is a known substance and can be prepared by a known method. For example, the compound of Formula 1 or a salt thereof may be prepared by hydrolyzing soybean lecithin and then purifying it to prepare glycerophosphocholine, followed by reaction with a fatty acid such as myristate. In addition, the compound of Formula 1 or a salt thereof may be commercially available (for example, Sigma-Aldrich).

The compound of the formula (1) or a pharmaceutically acceptable salt thereof may contain asymmetric carbon. In this case, the compound of the formula (1) or a salt thereof may be optically conjugated with an optically active compound such as (R), (S) Lt; / RTI > isomers. Accordingly, unless otherwise indicated, the compound of Formula 1 or a pharmaceutically acceptable salt thereof encompasses all optical isomers such as (R), (S), or racemic (RS).

The compound of formula (I) of the present invention may be in the form of a pharmaceutically acceptable salt. Such salts include the salts derived from inorganic acids such as conventional acid addition salts such as hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and the like and salts derived from citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, lactobionic acid, But are not limited to, salts with organic acids such as hydrochloric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid or aspartic acid. . The salt may also be in the form of a conventional metal salt, for example, an alkali metal salt such as lithium, sodium, or potassium; Alkaline earth metal salts such as calcium or magnesium salts; Or chromium salts.

The pharmaceutical composition of the present invention may further comprise, in addition to the compound of Formula 1 or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of bile acid or a pharmaceutically acceptable salt thereof as an active ingredient. Wherein the bile acid is selected from the group consisting of cholic acid, glycolic acid, glyco deoxycholic acid, deoxycholic acid, taurocholic acid, ursodeoxycholic acid, taurosoldoxycholic acid, taurodeoxycholic acid, cenodeoxy At least one member selected from the group consisting of cholic acid, glycolic acid, glycolic acid, glycoordoxoxycholic acid, sodium deoxycholate, and sodium taurocholate. Preferably, the bile acid or a pharmaceutically acceptable salt thereof is selected from the group consisting of glycocholic acid, deoxycholic acid, taurocholic acid, tauroursodeoxycholic acid, glycoordoxoxycholic acid, sodium deoxycholate, and ≪ RTI ID = 0.0 > sodium < / RTI > taurocholate. More preferably, the bile acid or a pharmaceutically acceptable salt thereof is at least one selected from the group consisting of glycolic acid, deoxycholic acid, tauroursodeoxycholic acid, sodium deoxycholate, and sodium taurocholate . Most preferably, the bile acid or a pharmaceutically acceptable salt thereof may be a glycolic acid and a taurocholic acid or a salt thereof (for example, a sodium salt). When the pharmaceutical composition of the present invention further comprises a bile acid or a pharmaceutically acceptable salt thereof as an active ingredient in addition to the compound of the above-mentioned general formula (1) or a pharmaceutically acceptable salt thereof, side effects such as tissue necrosis and inflammation The weight ratio of the compound of formula (I) or a pharmaceutically acceptable salt thereof to the bile acid or a pharmaceutically acceptable salt thereof is Can be in the range of 0.1 to 40: 1, preferably in the range of 1 to 35: 1, more preferably in the range of 1 to 20: 1, and still more preferably in the range of 1 to 10: 1.

The pharmaceutical composition of the present invention can be preferably administered parenterally, more preferably, topically, parenterally. The topical administration includes topical application under the eyes, under the chin, under the arms, hips, calves, back, thighs, ankles, abdomen and the like. For example, the pharmaceutical composition of the present invention may be formulated into a parenteral administration preparation (including a local administration preparation), and the parenteral administration preparation may be a transdermal preparation, a subcutaneous administration preparation, a intravenous administration preparation , A preparation for intramuscular administration or a preparation for intraperitoneal administration. In addition, the parenteral administration agent may be a single administration agent or a multiple administration agent. The preparation for multiple administration may be prepared to be administered at least once a day at intervals of 3 to 14 days in a volume of about 0.5 ml. If necessary, the preparation for parenteral administration may be repeatedly administered at 0.5 to 2.0 cm apart.

The parenteral dosage form may be in the form of a liquid preparation or a dry powder preparation. Such liquid preparations include solutions, emulsions, suspensions and the like, preferably in the form of solutions or emulsions. The liquid preparation may be aseptically filtered with a bacterial filter or the like and then filled into an ampule or vial. The dry powder preparation may be in the form of a powder obtained by drying a solution, emulsion, suspension or the like by rotary evaporation drying, spray drying, fluidized bed drying or freeze drying, It includes the form of a dry powder. The dry powder preparation may be administered orally or parenterally such as by injection water, sterilized distilled water, injection water, physiological saline, glucose solution, glucose injection, xylitol injection, D-mannitol injection, fructose injection, physiological saline, dextran injection, dextran injection, , Ringer's solution, lactic acid-Ringer's solution, and the like.

Formulations for parenteral administration in the form of liquid or dry powder formulations may be prepared according to a formulation method commonly used in the pharmaceutical industry using pharmaceutically acceptable additives and / or carriers. Accordingly, the pharmaceutical compositions of the present invention may comprise one or more pharmaceutically acceptable additives selected from the group consisting of pH adjusting agents, isotonic agents, surfactants, stabilizers, preservatives (or antibacterial agents), chelating agents, buffering agents and lyophilization stabilizing agents; And a pharmaceutically acceptable carrier selected from the group consisting of an oil, an organic solvent, and an aqueous solvent.

The pH adjusting agent includes a pH adjusting agent commonly used in injectable preparations, for example, but not limited to, sodium hydroxide, citric acid, acetic acid, phosphoric acid, gluconic acid, ascorbic acid, succinic acid and the like. The pharmaceutical composition of the present invention may have a pH in the range of pH 3 to pH 9, preferably in the range of pH 5 to pH 8, for example. A pharmaceutical composition having such a pH range can minimize pain and / or inflammation when administered topically.

Examples of the isotonic agent include sugars, sugar alcohols, salts and the like, and examples thereof include glucose, glycerin, sodium chloride, calcium chloride, sodium sulfate, glycerin, propylene glycol, polyethylene glycol (for example, polyethylene glycol having a molecular weight of 1000 or less) But are not limited to, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose, In one embodiment, the isotonicity agent may be glycerin and / or sodium chloride, and in particular, glycerin may help enhance the stability of the formulation. The isotonic agent may be used in an amount suitable to provide a physiologically acceptable osmotic pressure.

The surfactant includes ionic, nonionic, and / or amphoteric surfactants. In one embodiment, the surfactant may be a nonionic surfactant. The amphoteric surfactant may be, for example, a polyoxyethylene sorbitan fatty acid ester (for example, Tween series surfactants), a polyoxyethylene-polyoxypropylene block copolymer (for example, (Poloxamer series surfactants)], and the like, but are not limited thereto.

Such stabilizers include, but are not limited to, for example, cholesterol,? -Cholesterol, cystosterol, ergosterol, stigmasterol, stigmasterol acetate, lanosterol, and combinations thereof. In one embodiment, the stabilizing agent may be cholesterol.

Such preservatives include antimicrobial agents commonly used in the pharmaceutical arts. The preservative may be selected from the group consisting of benzyl alcohol, glycerin, m-cresol, phenol, benzalkonium chloride, benzethonium chloride, acacia, albumin, alcohol, alginic acid, ascorbyl palmitate, aspartame, boric acid, citric acid, glycerin, But are not limited to, sodium, sorbic acid, chlorobutanol, o-cresol, p-cresol, chlorocresol, benzalkonium chloride, phenylmercuric acid nitrate, thimerosal, benzoic acid, cholesterol and the like. In one embodiment, the preservative may be benzyl alcohol and / or glycerin.

The chelating agent may be ethylenediaminetetraacetic acid (EDTA), buthylenediaminetetraacetic acid (EDTA), cyclohexane-1,2-diaminetetraacetic acid (CyDTA), diethylene glycol diethylenetriacetate (Hydroxyethyl) ethylenediaminetriacetic acid, N, N, N ', N'-ethylenediamine tetra (methylenephosphone) (EDTMP), ethylenediaminetetra (methylenephosphonic acid), triethylenetetraminehexaacetic acid (TTHA), 1,3-diamino-2-hydroxypropan-N, N, N ', N'-tetraacetic acid DHPTA, 1,3-diamino-2-hydroxypropane-N, N, N'-tetracetic acid, methyliminodiacetic acid, propylenediaminetetracetic acid, Triazacyclo N, N ', N''-tris (methylenephosphonic acid) (DOTRP; 1,5,9-triazacyclodecane- N, N ', N' ', N' '' - tetrakis (methylenephosphonic acid) (DOTP; 1,4,7,10-tetraazacyclodecane- N, N'-tetrakis (methylenephosphonic acid), nitrilotris (methylene) triphosphonic acid, diethylenetriaminephenta (methylenephosphonic acid) (Methylenephosphonic acid), 1-hydroxyethylene-1,1-diphosphonic acid, bis (hexamethylene) triaminephosphonic acid bis (hexamethylene) triaminephosphonic acid, 1,4,7-triazacyclononane-N, N ', N "-tris (methylenephosphonic acid) (NOTP; N, N ', N "-tris (methylenephosphonic acid), 2-phosphonobutane-1,2,4- tricarboxylic acid, nitrilotriacetic acid (NTA), citric acid, fumaric acid, malic acid, maltol, tartaric acid, gluconic acid, Glyceric acid, oxalic acid, phthalic acid, maleic acid, mandelic acid, malonic acid, ractic acid, salicylic acid, acid, salicylate, 5-sulfosalicylic acid, galic acid, propylgallate, pyrogallol, 8-hydroxyquinoline, Cysteine, and the like, but are not limited thereto.

The buffer may be selected from the group consisting of dibasic sodium phosphate, citric acid, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium carbonate, calcium carbonate, tribasic calcium phosphate, calcium lactate, glycine, maleic acid, malic acid, sodium glutamate, But are not limited to, monosodium, sodium lactate, sodium phosphate, and mixtures thereof.

The cryoprotectant may be a sugar, a sugar alcohol or a mixture thereof. The sugar may be selected from the group consisting of lactose, maltose, sucrose, mannose, trehalose, xylose, fructose, and raffinose. The sugar alcohol may be selected from the group consisting of mannitol, sorbitol, inositol, maltitol, xylitol And < RTI ID = 0.0 > lactitol. ≪ / RTI > The lyophilized protective agent may further include, but is not limited to, glycine, histidine, polyvinylpyrrolidone (PVP), and the like.

The organic solvent may be at least one selected from the group consisting of alcohols such as ethanol (including anhydrous, fermented alcohol), methanol, acetone, diacetone, octanol, isopropyl alcohol, lauryl alcohol and polyvinyl alcohol; But are not limited to, glycols such as polyethylene glycol, ethylene glycol, propylene glycol, dipropylene glycol, butylene glycol, pentylene glycol, thioglycolic acid and the like.

Such oils include, but are not limited to, vegetable oils, medium chain triglycerides (MCTs), cholesterol, glyceryl stearate, oleic acid, and the like. In one embodiment, the oil may be a vegetable oil and / or oleic acid. The vegetable oil may be selected from the group consisting of cottonseed oil, corn oil, sesame oil, soybean oil, olive oil, coconut oil, peanut oil, sunflower oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, barba milk, beech nut oil, Flaxseed oil, canola oil, and combinations thereof. In one embodiment, the vegetable oil may be soybeans unique.

The aqueous solvent includes, but is not limited to, water for injection, sterile distilled water, saline, aqueous dextrose or aqueous sucrose.

The pharmaceutical composition of the present invention is usually contained in a sealed, sterilized plastic or organic container. The container may be provided in the form of a defined volume, such as an ampoule, vial, syringe or cartridge, or may be provided in a large volume form such as a used bag or bottle.

In the pharmaceutical composition of the present invention, the therapeutically effective amount of the compound of Formula 1 or a pharmaceutically acceptable salt thereof may range from about 1 mg / kg to about 1,500 mg / kg per day, Weight, susceptibility, symptom or form of the preparation, and the like. In one embodiment, the compound of Formula 1 or a pharmaceutically acceptable salt thereof may be included in the range of 1 to 1,000 mg, preferably 1 to 500 mg, per unit dosage form. In addition, the therapeutically effective amount of the bile acid or a pharmaceutically acceptable salt thereof can be appropriately determined in consideration of the weight ratio with the compound of the formula (1) or a pharmaceutically acceptable salt thereof as described above.

The present invention also relates to a method of inducing lipolysis or a method of inducing lipolysis comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof, And methods of treating obesity.

In the treatment method of the present invention, the compound of Formula 1 is 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1,2-diylcoyl-sn-glycero-3-phosphocholine; 1,2-diolureo-sn-glycero-3-phosphocholine; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; And 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. More preferably, the compound of Formula 1 is 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; And 1,2-dilauroyl-sn-glycero-3-phosphocholine. Most preferably, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine.

The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the induction of lipid degradation or prevention or treatment of obesity.

In the use of the present invention, the compound of Formula 1 is 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine; 1,2-diylcoyl-sn-glycero-3-phosphocholine; 1,2-diolureo-sn-glycero-3-phosphocholine; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; And 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine. More preferably, the compound of Formula 1 is 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine; 1,2-didecanoyl-sn-glycero-3-phosphocholine; 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine; And 1,2-dilauroyl-sn-glycero-3-phosphocholine. Most preferably, the compound of Formula 1 may be 1,2-dimyristoyl-sn-glycero-3-phosphocholine.

Hereinafter, the present invention will be described in more detail through examples and test examples. However, the following examples and test examples are provided for illustrating the present invention, and the present invention is not limited thereto.

Example  1. Preparation of freeze-dried preparations

According to the ingredients and contents in Table 1 below, a freeze-dried preparation having a lyophilized powder form was prepared. The contents in Table 1 represent the weight (mg) of each component. Ethanol (50 ml) was stirred at 300 rpm to dissolve oleic acid, glycerin, cholesterol, and benzyl alcohol. The obtained solution was heated to 70 占 폚 to dissolve DMPC to prepare a first solution.

The obtained first solution was added to 800 mL of water for injection in which mannitol (62.5 mg) was dissolved and homogenized at 15,000 rpm for about 60 minutes using a homogenizer Unidrive x1000D display (CAT GmbH, German) . The resulting emulsion was aseptically filtered with a membrane filter (PVDF 0.22 μm filter, Millipore, USA) and lyophilized under the following conditions to obtain a preparation in the form of a lyophilized powder. The lyophilized formulation obtained was stored in a 10 ml vial.

Example  2 to 18. Preparation of freeze-dried preparations

According to the ingredients and contents in Tables 1 and 2 below, a freeze-dried preparation having a lyophilized powder form was prepared. The contents of Table 1 and Table 2 represent the weight (mg) of each component. A first solution was prepared in the same manner as in Example 1 using DMPC or other phosphocholine derivatives.

Sodium diphosphate, sodium chloride and sodium hydroxide were dissolved in a separate vessel while stirring the injection water (150 ml) at 300 rpm. The second solution was prepared by dissolving bile acid or its salt in the obtained solution.

The first solution (50 ml) and the second solution (150 ml) were heated to 70 ± 10 ° C, mixed and homogenized at 10,000 rpm using a homogenizer Unidrive x1000D display, CAT GmbH, Homogenized for 30 minutes to obtain an emulsion. The obtained emulsion was added to 800 mL of water for injection in which 62.9 mg of mannitol was dissolved and homogenized at 15,000 rpm for about 60 minutes using a high-pressure homogenizer (Homogenizer Unidrive x1000D display, CAT GmbH, German) to obtain an emulsion. The obtained emulsion was aseptically filtered with a membrane filter (PVDF 0.22 μm filter, Millipore, USA) and lyophilized under the same conditions as in Example 1 to obtain a preparation in the form of a lyophilized powder. The lyophilized formulation obtained was stored in a 10 ml vial.

Example One 2 3 4 5 6 7 8 The first solution
(Oil solution) DMPC 150 150 150 150 150 200 100 100 DPPC - - - - - - - - SMPC - - - - - - - - DDPC - - - - - - - - PSPC - - - - - - - - DLPC - - - - - - - - glycerin One One One One One One One One Benzyl alcohol 9 9 9 9 9 9 9 9 Oleic acid 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 cholesterol 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 Ethanol (ml) 50 50 50 50 50 50 50 50 The second solution
(Aqueous solution) Sodium deoxycholate - - - - 15.4 - - - Sodium taurocholate - 20 - - - 50 20 10 Glycocholic acid - - 17.3 - - - - - Taururous deoxycholic acid - - - 18.6 - - - - Sodium secondary phosphate - 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Sodium chloride - 4.4 4.4 4.4 4.4 4.4 4.4 4.4 Sodium hydroxide - 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Injection water (containing 62.9 mg mannitol, ml) 800 800 800 800 800 800 800 800 Phosphocholine derivatives: bile acid (weight ratio) - 15: 2 15: 2 15: 2 15: 2 4: 1 5: 1 10: 1

Example 9 10 11 12 13 14 15 16 17 18 The first solution
(Oil solution) DMPC 150 120 100 200 120 - - - - - DPPC - - - - - 139.3 - - - - SMPC - - - - - - 139.3 - - - DDPC - - - - - - - 107.4 - - PSPC - - - - - - - - 144.7 - DLPC - - - - - - - - - 118.0 glycerin One One One One One One One One One One Benzyl alcohol 9 9 9 9 9 9 9 9 9 9 Oleic acid 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 cholesterol 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 Ethanol (ml) 50 50 50 50 50 50 50 50 50 50 The second solution
(Aqueous solution) Sodium deoxycholate - - - - - - - - - - Sodium taurocholate 70 20 100 150 40 20 20 20 20 20 Glycocholic acid - - - - - - - - - - Taururous deoxycholic acid - - - - - - - - - - Sodium secondary phosphate 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Sodium chloride 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 Sodium hydroxide 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Injection water
(Containing 62.9 mg of mannitol, ml) 800 800 800 800 800 800 800 800 800 800 Phosphocholine derivatives: bile acid
(Weight ratio) 2.5: 1 6: 1 1: 1 4: 3 3: 1 15: 2 15: 2 15: 2 15: 2 15: 2

Example  19. Preparation of solution

According to the ingredients and contents in Table 3 below, formulations with solution forms were prepared. The contents in Table 3 represent the weight (mg) of each component. Benzyl alcohol and Tween 80 were dissolved in injectable water (7-8 ml) heated to about 30 ° C, DMPC was added, and the mixture was stirred and dissolved at 300 rpm for about 1 hour. The pH of the solution was adjusted by dissolving sodium phosphate, sodium chloride and sodium hydroxide while the temperature of the obtained solution was warmed to about 30 ° C, and the final volume was adjusted to 10 ml with the water for injection. The resulting solution was aseptically filtered through a membrane filter (PVDF 0.22 μm filter, Millipore, USA) and filled into vials.

Example  20 to 36. Preparation of solution

According to the ingredients and contents in the following Tables 3 and 4, preparations having a solution form were prepared. The contents of Table 3 and Table 4 represent the weight (mg) of each component. Benzyl alcohol and Tween 80 were dissolved in water (7-8 ml) which was warmed to about 30 ° C, and bile acid or its salt was added thereto and dissolved by stirring at 300 rpm for about 1 hour to dissolve the second solution. DMPC or other phosphocholine derivatives were added while the temperature of the obtained second solution was warmed to about 30 占 폚, and the solution was stirred and dissolved at 300 rpm for 1 hour. Sodium phosphate, sodium chloride and sodium hydroxide were dissolved in the resulting solution to adjust the pH and the like, and the final volume was adjusted to 10 ml with an injection water. The resulting solution was aseptically filtered through a membrane filter (PVDF 0.22 μm filter, Millipore, USA) and filled into vials.

Example 19 20 21 22 23 24 25 26 The first solution DMPC 150 150 150 150 150 200 100 100 DPPC - - - - - - - - SMPC - - - - - - - - DDPC - - - - - - - - PSPC - - - - - - - - DLPC - - - - - - - - Sodium secondary phosphate 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Sodium chloride 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 Sodium hydroxide 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 The second solution Sodium deoxycholate - - - - 15.4 - - - Sodium taurocholate - 20 - - - 50 20 10 Glycocholic acid - - 17.3 - - - - - Taururous deoxycholic acid - - - 18.6 - - - - Benzyl alcohol 9 9 9 9 9 9 9 9 Tween 80 27.5 27.5 27.5 27.5 27.5 27.5 27.5 27.5 Injection water (final volume, ml) 10 10 10 10 10 10 10 10 Phosphocholine derivatives: bile acid (weight ratio) - 15: 2 15: 2 15: 2 15: 2 4: 1 5: 1 10: 1

Example 27 28 29 30 31 32 33 34 35 36 The first solution DMPC 150 120 100 200 120 - - - - - DPPC - - - - 139.3 - - - - SMPC - - - - - 139.3 - - - DDPC - - - - - - 107.4 - - PSPC - - - - - - - 144.7 - DLPC - - - - - - - - 118.0 Sodium secondary phosphate 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Sodium chloride 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 Sodium hydroxide 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 The second solution Sodium deoxycholate - - - - - - - - - - Sodium taurocholate 70 20 100 150 40 20 20 20 20 20 Glycocholic acid - - - - - - - - - - Taururous deoxycholic acid - - - - - - - - - - Benzyl alcohol 9 9 9 9 9 9 9 9 9 9 Tween 80 27.5 27.5 27.5 27.5 27.5 27.5 27.5 27.5 27.5 27.5 Injection water (final volume, ml) 10 10 10 10 10 10 10 10 10 10 Phosphocholine derivatives: bile acid (weight ratio) 2.5: 1 6: 1 1: 1 4: 3 3: 1 15: 2 15: 2 15: 2 15: 2 15: 2

Comparative Example  One

A solution containing phosphatidylcholine was prepared in the same manner as in Example 19, except that phosphatidylcholine (150 mg) was used instead of DMPC.

Comparative Example  2

A solution containing phosphatidylcholine and sodium deoxycholate was prepared in the same manner as in Example 20 except that phosphatidylcholine (150 mg) was used instead of DMPC and sodium deoxycholate (20 mg) was used instead of sodium taurocholate Respectively.

Test Example  1. Measurement of lipolytic activity

1. Preparation and administration of animal models

Sprague-Dawley rats (4 weeks old, Orient Biotech, Seongnam, South Korea) were fed high fat diet (D12492, 5% calories from fat, 20% calories from protein, and 35% Calorie from carbohydrates, RESEARCH DIET Inc., New Brunswick, NJ, USA). The rats were fed a 12 hour / 12 hour cancer cycle under the conditions of 20.0-24.0 ° C, 40-60% relative humidity, and water was fed ad libitum. The body weight of each rat was monitored weekly, resulting in an elevated obesity state (feed 9 weeks, total 13 weeks). The average weight of the rats (n = 10) in each group of the final 13 weeks is as shown in Table 5 below.

After induction of the high obesity state as described above, 0.2 mL of each of the control group without the active ingredient, the preparation of Examples 1 to 36, and the preparations of Comparative Examples 1 and 2 was divided into highly obese rats (n = 10 rats ) Were subcutaneously injected once a week for 4 weeks in the left groin. The preparations of Examples 1 to 18 were subcutaneously injected into the injection water (10 mL) by redissolving the lyophilized powder.

Group (n = 10) Average weight (9th week, 13 weeks old) Administered preparation Group 1 691.90 g Example 1 Group 2 682.77 g Example 2 Group 3 680.71 g Example 3 Group 4 685.40 g Example 4 Group 5 683.20 g Example 5 Group 6 684.10 g Example 6 Group 7 681.50 g Example 7 Group 8 682.50 g Example 8 Group 9 707.02 g Example 9 Group 10 700.86 g Example 10 Group 11 686.95 g Example 11 Group 12 682.94 g Example 12 Group 13 698.25 g Example 13 Group 14 683.30 g Example 14 Group 15 701.15 g Example 15 Group 16 693.26 g Example 16 Group 17 688.22 g Example 17 Group 18 689.10 g Example 18 Group 19 688.40 g Example 19 Group 20 690.54 g Example 20 Group 21 690.91 g Example 21 Group 22 688.71 g Example 22 Group 23 690.65 g Example 23 Group 24 683.74 g Example 24 Group 25 685.75 g Example 25 Group 26 690.48 g Example 26 Group 27 689.58 g Example 27 Group 28 688.74 g Example 28 Group 29 687.15 g Example 29 Group 30 688.97 g Example 30 Group 31 687.65 g Example 31 Group 32 692.85 g Example 32 Group 33 698.55 g Example 33 Group 34 697.40 g Example 34 Group 35 694.15 g Example 35 Group 36 699.30 g Example 36 Group 37 688.97 g Comparative Example 1 Group 38 687.65 g Comparative Example 2 Group 39 704.84 g Control group

2. Evaluation of adverse effects and lipolysis effects

After two weeks of recovery, the rats in each group were sacrificed, followed by observation of inflammation and necrosis, measurement of fat reduction rate at the site of administration, hematoxylin and eosin stain, and oil red O Oil Red O) reaction and inflammation were evaluated.

(1) Observation of inflammation and necrosis

After 2 weeks of recovery period after completion of 4 weeks of administration, the rats in each group were sacrificed and the subcutaneous injection site was observed with naked eyes and tactile senses. As a result, necrosis and inflammation were not observed at the injection site in the group to which the preparation of the present invention was administered, and the hard part was not touched even during the tactile test. On the other hand, in the group administered with the preparations of Comparative Examples 1 and 2, necrosis and inflammation were visually observed at the injection site, and also changed severely and firmly during the tactile test.

(2) Measurement of fat reduction rate

After 2 weeks of recovery period after completion of 4 weeks of administration, the rats in each group were sacrificed and tissue autopsy was performed. The inguinal subcutaneous tissues of the right and left sides (the site of administration) were visually observed for abnormal findings and photographs were taken. The tissue was then harvested and weighed. Relative weight and reduction rate were calculated according to the following formula, and the results are shown in Table 6 below. The photographing results are shown in Fig.

Relative weight (g) = inguinal fat weight (g) / weight (g)

Reduction rate (%) = [1- (left (g) / right (g))] 100%

Ingredients Fat Weight (g) Relative weight (g) Decrease (%) Left (site of administration) Right Left (site of administration) Right Example 1 4.0052 5.1944 0.0057 0.0075 22.89% Example 2 3.5511 4.6151 0.0051 0.0068 23.05% Example 3 3.7515 4.8670 0.0054 0.0071 22.92% Example 4 3.7748 4.8842 0.0055 0.0071 22.71% Example 5 3.7185 4.8186 0.0054 0.0071 22.83% Example 6 3.3555 4.4451 0.0050 0.0065 24.51% Example 7 3.7388 4.7849 0.0055 0.0070 21.86% Example 8 3.4773 4.4146 0.0051 0.0065 21.23% Example 9 3.7266 4.8236 0.0054 0.0068 22.74% Example 10 3.8009 4.8186 0.0054 0.0069 21.12% Example 11 3.8482 4.8467 0.0058 0.0071 20.60% Example 12 3.7877 4.9839 0.0058 0.0073 24.00% Example 13 4.2999 5.4665 0.0065 0.0078 21.34% Example 14 3.7844 4.8632 0.0056 0.0071 22.18% Example 15 4.0191 5.1944 0.0057 0.0074 22.63% Example 16 3.7736 4.8670 0.0054 0.0070 22.47% Example 17 3.8523 4.9530 0.0056 0.0072 22.22% Example 18 3.5764 4.6151 0.0052 0.0067 22.51% Example 19 3.6078 4.6151 0.0051 0.0067 21.83% Example 20 4.0087 5.1944 0.0057 0.0075 22.83% Example 21 3.9466 5.0512 0.0056 0.0073 21.87% Example 22 3.9659 5.0706 0.0058 0.0074 21.79% Example 23 4.0636 5.2003 0.0059 0.0075 21.86% Example 24 3.9815 5.2360 0.0060 0.0077 23.96% Example 25 4.1056 5.1575 0.0060 0.0075 20.40% Example 26 3.9893 4.9960 0.0058 0.0072 20.15% Example 27 3.8761 4.9599 0.0057 0.0072 21.85% Example 28 3.9919 5.0510 0.0059 0.0073 20.97% Example 29 3.9212 4.8866 0.0059 0.0071 19.76% Example 30 3.8077 5.0005 0.0059 0.0073 23.85% Example 30 3.9543 4.9999 0.0060 0.0073 20.91% Example 32 3.9144 4.9891 0.0057 0.0072 21.54% Example 33 3.8763 4.9087 0.0055 0.0070 21.03% Example 34 3.9013 4.9886 0.0056 0.0072 21.80% Example 35 3.9977 5.1201 0.0059 0.0074 21.92% Example 36 3.9711 5.0807 0.0058 0.0073 21.84% Comparative Example 1 4.8875 5.0210 0.0070 0.0073 4.03% Comparative Example 2 4.8991 5.0708 0.0070 0.0074 5.37% Control group 4.8814 4.9864 0.0069 0.0071 2.11%

As shown in Table 6, the group administered with the agent of the present invention showed a remarkable decrease in the organ weight and relative weight at the administration site, and thus it can be confirmed that the lipid-lowering activity was excellent. Furthermore, as shown in Fig. 1, it can be confirmed that the lipidolytic activity of the site of administration (dark circle) is remarkably excellent when compared with the non-administration site (circle marked with a dotted line)

(3) H & E staining ( Hematoxylin  and eosin stain)

The abdomen and inguinal region of the rats were dissected and the subcutaneous fat was rapidly removed and immersed in a 10% neutral buffered formaldehyde solution. After washing with water and dehydrated, the cells were treated with paraffin solution to make a paraffin block. The paraffin block was cut to a thickness of 4-5 μm, stained with hematoxylin and eosin, and observed with an optical microscope . As a result, as shown in FIG. 2, most of intact adipocytes were observed in the group to which the formulation of the present invention was administered, whereas inflammatory reaction findings were observed in the group administered with the preparations of Comparative Examples 1 and 2.

(4) Oils Red  O (Oil Red O) Reaction

The abdominal region and inguinal region of the sacrificed rats were dissected and the subcutaneous fat was rapidly removed. The inguinal fat tissues were fixed in 4% formaldehyde for 24 hours, dehydrated for 24 hours using 30% sucrose, and then cryotomized (FSE Cryostats, Thermo Scientific) to prepare OCt-embedding cryostat. The slides were prepared to a thickness of 10 μm and stained with fat red O (Lipid Stain) dye kit (ab150678, abcam, USA) and the degree of lipid degradation was observed using an optical microscope. As a result, as shown in FIG. 3, the group administered with the formulation of the present invention showed a uniform distribution of fat, whereas the group administered with the preparations of Comparative Examples 1 and 2 did not show uniform fatty decomposition can confirm. Therefore, it can be confirmed that the preparations of the present invention uniformly decompose the fat at the administration site, but the preparations of Comparative Examples 1 and 2 do not achieve uniform fat decomposition.

Test Example  2. Stability test

The formulations of Examples 1 to 4, 6, 12, 19 to 22, 24, 26, 28, 30 and the preparations of Comparative Examples 1 and 2 were stored at room temperature for 7 days and 30 days. The preparations of Examples 1 to 4, 6 and 12 were stored in the solution for injection (10 ml). The results for the initial manufacture of each formulation, storage at room temperature for 7 days, and storage at room temperature for 30 days are shown in FIG. From the results shown in Fig. 4, it can be seen that the preparation of the present invention has excellent stability.

Claims (7)

Claims 1. A pharmaceutical composition for preventing or treating local obesity comprising 1,2-dilauryl-sn-glycero-3-phosphocholine or a pharmaceutically acceptable salt thereof as an active ingredient, Wherein the pharmaceutical composition is formulated as a topical preparation selected from the group consisting of an agent for administration, an agent for intramuscular administration, and an agent for intraperitoneal administration. 2. The pharmaceutical composition according to claim 1, wherein the active ingredient is at least one selected from the group consisting of glycolic acid, deoxycholic acid, taurocholic acid, tauroursodeoxycholic acid, glyco-soroxylic acid, sodium deoxycholate, and sodium taurocholate Lt; RTI ID = 0.0 > pharmaceutically < / RTI > acceptable salt thereof. 3. The pharmaceutical composition according to claim 2, wherein the bile acid or a pharmaceutically acceptable salt thereof is sodium deoxycholate or sodium taurocholate. 3. The method according to claim 2, wherein the weight ratio of the 1,2-dilauroyl-sn-glycero-3-phosphocholine or a pharmaceutically acceptable salt thereof to the bile acid or a pharmaceutically acceptable salt thereof is 0.5 To 40: 1. ≪ RTI ID = 0.0 > 5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the preparation for topical administration is in the form of a liquid preparation or a dry powder preparation. 5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the preparation for topical administration is in the form of a solution, an emulsion or a lyophilized powder. 5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the preparation for topical administration is at least one selected from the group consisting of pH adjusting agents, isotonizing agents, surfactants, stabilizers, preservatives, chelating agents, buffering agents and freeze- A pharmaceutically acceptable additive; And a pharmaceutically acceptable carrier selected from the group consisting of an oil, an organic solvent, and an aqueous solvent.

Images